The Children’s Anti-Inflammatory REliever (CARE) Study
Thank you for visiting the Children’s Anti-Inflammatory REliever (CARE) study information page. The CARE study is now fully recruited and unable to accept enquires for more participants.
If your child uses or has recently used a preventer inhaler for their asthma they may be eligible for our START CARE study. If you would like to find out more about this study, please click here for more information.
If you wish to register interest for future children’s asthma trials, please click here to leave your details.
WHat is this study about?
With the CARE study, we are comparing two different inhalers to find out which one is better at preventing asthma attacks in children:
Ventolin (a commonly used “blue” reliever inhaler/puffer)
Symbicort Rapihaler (similar to the Symbicort Turbuhaler, which is often used as a reliever inhaler by adults with asthma)
Participants will be given one of these inhalers (decided at random) to take for one year. They do not have to take the inhaler everyday – only when they have asthma symptoms.
If your child’s asthma is bad, or they have an asthma attack, we might want to also give them a preventer inhaler, or increase how often they take their study inhaler.
During the study, we will meet with each participant 5 times (3 times in-person or via video, and two times via telephone) to see how they are getting on. We will ask questions about their asthma and perform some breathing tests.
All study medication is provided free-of-charge during the study, and parents/guardians will be reimbursed for their travel expenses.
Who can take part?
For your child to take part, they must:
Be between 5 years and 15 years old
Have asthma
Currently only using a reliever inhaler/puffer (such as Ventolin, Respigen, or Bricanyl). If they have a preventer inhaler (e.g. a Flixotide steroid inhaler) but haven’t used it in the last six months, then they may still be able to take part.
Who can’t take part?
This study isn’t suitable for everyone. Your child would not be able to take part if they:
Have finished more than 6 reliever inhalers (used all the actuations/puffs) within a year
Have been admitted to hospital (for more than 24 hours) due to asthma in the past year
Have ever been admitted to intensive care for asthma
Are pregnant
Have a serious medical condition, such as Cystic Fibrosis
Where is the study taking place?
|
Region |
Site |
Address |
Contact |
|
Auckland |
Optimal Clinical Trials |
Level 2/97 Grafton Road, Grafton, Auckland 1010 |
Sharin Asadi
|
|
SCT Totara |
1 McCrae Way, Level 1, New Lynn, Auckland 0600 |
Sunny Bu
|
|
|
Waitemata Clinical Research |
29 Birkenhead Avenue, Birkenhead, Auckland 0626 |
Niklas Gemmell
|
|
|
Bay of Plenty |
Clinical Horizons |
223 Otumoetai Road, Otumoetai, Tauranga 3110 |
Tracy Paterson
|
|
LCT Rotorua |
1289 Haupapa Street, Rotorua 3010 |
Heather Boyce
|
|
|
Waikato |
LCT Waikato |
6 Avalon Drive, Nawton, Hamilton 3200 |
Dr Tiwini Hemi
|
|
Hawke’s Bay |
MRINZ Hawke’s Bay |
Taradale Medical Centre, 2024 Puketapu Road, Taradale Napier |
Melissa Black
|
|
Manawatu |
P3 Palmerston North |
273 Broadway Avenue, Palmerston North Central, Palmerston North 4414 |
Kirsten Moffitt
|
|
Wellington |
P3 Research Kāpiti |
44A Ihakara Street, Paraparaumu 5032 |
Sonja Dreyer
|
|
MRINZ Lower Hutt |
Lower Hutt After Hours Medical Centre, 729 High Street, Boulcott, Lower Hutt 5010 |
Karen Oldfield
|
|
|
MRINZ Wellington |
Wellington Regional Hospital, 49 Riddiford Street, Newtown, Wellington 6021 |
Karen Oldfield
|
|
|
MRINZ Porirua |
Maraeroa Marae Clinic, 216 Warspite Avenue, Waitangirua, Porirua 5024 |
Rebekah Lamb
|
|
|
Tasman |
MRINZ Motueka |
Greenwood Health, 20 Greenwood Street, Motueka 7120 |
Richard Fuller
|
|
SCT Tasman |
469 Main Road, Stoke, Nelson 7011 |
Stephanie Stephens
|
|
|
Canterbury |
SCT Forte |
132 Peterborough Street, Christchurch Central 8013 |
Andrea Wallace
|
|
Dunedin |
P3 Dunedin |
Unit 2/401 Moray Place, Central Dunedin, Dunedin 9016 |
Sue Walker
|
|
Other |
Remote |
Participate from home |
Karen Oldfield
|
Ethics: Approved by the Northern B Health and Disability Ethics Committee (20/NTB/200).
Funding: Health Research Council of New Zealand (20/389) and Cure Kids.
